CPC Scientific Brings Peptide and Oligonucleotide CRDMO Solutions to TIDES Europe 2025

Rocklin, CA — CPC Scientific Inc., a global leader in peptide and oligonucleotide CRDMO services, will exhibit at TIDES Europe 2025 in Basel, Switzerland, from November 11–13. The company will showcase its advanced development and GMP manufacturing capabilities supporting peptide, oligonucleotide, and conjugate therapeutics from early development through commercial scale.

CPC Scientific’s participation underscores its ongoing commitment to driving innovation, quality, and partnership within the rapidly evolving TIDES sector. The team looks forward to connecting with partners and clients to discuss new opportunities in peptide and oligonucleotide development.

What attendees can expect

At TIDES Europe 2025, CPC Scientific’s team will be available to discuss its comprehensive peptide and oligonucleotide CDMO services, spanning discovery to GMP manufacturing. Attendees can learn more about the company’s expertise in scale-up strategy, process optimization, analytical development, and regulatory compliance, as well as its flexible partnership models that support programs from early research through commercialization.

Building Partnerships for the Future of Therapeutics

CPC Scientific views TIDES Europe as a key opportunity to connect with organizations advancing innovative peptide and oligonucleotide therapeutics to meet unmet medical needs. The company’s dedication to scientific excellence, regulatory compliance, and collaborative partnerships has established CPC Scientific as a trusted global CRDMO supporting biopharmaceutical innovators worldwide.

Attendees interested in learning more about CPC Scientific’s capabilities are invited to visit the company’s booth #327 throughout the conference. The team will be available for one-on-one discussions about specific project requirements and partnership opportunities.

To book a meeting, email [email protected] or visit https://cpcscientific.com/event/tides-europe/.

About CPC Scientific, Inc.

With nearly 25 years of experience, CPC Scientific Inc. is a globally recognized Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in synthetic GMP peptides, oligonucleotides, and peptide-oligonucleotide conjugates (POCs), while also providing a full range of research-grade custom and catalog products. Building on a proven track record of excellence, CPC Scientific has supported clients in advancing hundreds of innovative new chemical entities into GMP development. With more than 300 active pipelines spanning preclinical to Phase III studies and 13 commercial projects, the company continues to demonstrate its commitment to scientific innovation, quality, and therapeutic progress.

The group’s integrated service model is designed to support partners through the most critical stages of drug development, with a particular focus on late-phase development, large-scale manufacturing, and commercial production. From early discovery to full commercialization at metric-ton scale, the company provides the expertise and infrastructure needed to accelerate peptide and oligonucleotide programs toward success.

CPC Scientific meticulously follows FDA and ICH guidelines for cGMP manufacturing and provides complete support for IND and NDA filings in the USA and all international regulatory documentation required for active pharmaceutical ingredients (APIs). Its New Chemical Entity (NCE) development program involves process development, process validation, analytical method development, method validation, stability studies, regulatory support, and assistance preparing regulatory documents.

CPC Scientific’s core ethos centers on the understanding that time to market is critical to every project’s success. The company prioritizes flexibility, pre-qualified facilities, and robust supply chains to efficiently onboard new projects and initiate production without delay.

With a USA facility in Rocklin, near Sacramento, California, CPC Scientific is a subsidiary of Medtide Inc., which officially listed on the main board of the Hong Kong Stock Exchange in 2025.

Learn more at: https://cpcscientific.com

Resources

Click on Meet CPC Scientific in Basel to book a meeting with the event team.
Click on CPC Scientific News and Articles to see latest News & Events.